Aurobindo Pharma’s wholly owned arm Helix Healthcare will acquire an additional 20% stake in Luoxin Aurovitas Pharma in China for $5.1 million, strengthening its inhalation manufacturing footprint.
Aurobindo Pharma’s wholly owned arm Helix Healthcare will acquire an additional 20% stake in Luoxin Aurovitas Pharma in China for $5.1 million, strengthening its inhalation manufacturing footprint.